As early as 2024, the Federal Institute for Drugs and Medical Devices (BfArM) reported that there were ongoing supply bottlenecks for the drug LAMOTRIGIN ACIS® 50 MG. You can find out why there are restrictions and what the medicine is used for here on news.de!
Supply bottlenecks for medicines are now also an increasing challenge for the healthcare system in Germany. Image: AdobeStock_Africa Studio
In Germany, too, supply bottlenecks for medicines are now an increasing challenge for the healthcare system. More and more patients are having to forego important medications or switch to alternative treatments because the medicines they need are not available. Some have been missing for a few months, others can be delivered again quite quickly. LAMOTRIGIN ACIS® 50 MG is currently also affected by this.
Delivery bottleneck for the drug LAMOTRIGIN ACIS® 50 MG: “Inadequate production capacities”
The notification about the supply bottleneck of the drug is currently from acis Pharmaceuticals GmbH in force for the period from January 19, 2024 to March 8, 2024. The delivery deficit is particularly critical because the drug is urgently needed in hospitals. The Federal Institute did not suggest an alternative preparation for LAMOTRIGIN ACIS® 50 MG. In any case, it can be useful to look for alternatives at the pharmacy. In any case, the following should be noted: Always seek professional advice before purchasing products.
Various factors, individually or in combination, can lead to a supply shortage for a particular medication. For LAMOTRIGIN ACIS® 50 MG, the BfArM reports “insufficient production capacities” as the reason for the current delivery difficulties.
LAMOTRIGIN ACIS® 50 MG: The details about the medication
Lamotrigine acis® 50 mg is a prescription medicine and is particularly important because of its active ingredient, lamotrigine.
For example, the medicine is prescribed for the following diagnoses:
- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple focal seizures
- Bipolar affective disorder, unspecified
- Bipolar affective disorder, current mild or moderate depressive episode
- Generalized idiopathic epilepsy and epileptic syndromes
- Depressive episode, unspecified
- Petit mal seizures, unspecified, without grand mal seizures
- Other generalized epilepsy and epileptic syndromes
| drug | LAMOTRIGIN ACIS® 50 MG |
|---|---|
| Manufacturer | acis Pharmaceuticals GmbH |
| PZN | 04051810 |
| active ingredient | Lamotrigine |
| Validity period | January 19, 2024 to March 8, 2024 |
| relevant in the hospital | Yes |
| Alternative preparation | not specified |
| Reason for the delivery bottleneck | Insufficient production capacity |
When will the medication be available again?
Since the shortage in the LAMOTRIGIN ACIS® 50 MG case may last longer, it remains unclear whether the current validity period will be maintained.
Pharmacies are currently facing a particular challenge and must respond to the bottlenecks with smart decisions. For some medications it is possible to deviate from the prescribed pack size or to provide alternatives. Although this seems to be working well at the moment, this temporary solution should not become a lasting solution to the problems.
Efforts to curb drug supply shortages have been going on for some time. There are now laws and strategy papers at both national and European levels. Both immediate measures and long-term strategies were recorded. It will be interesting to see how the implementation of the new regulations affects the problem.
You can read everything about the topic of medication shortages here and here on news.de.
follow News.de already at Facebook, Twitter, Pinterest and YouTube? Here you will find hot news, current videos and a direct line to the editorial team.
+++ Editorial note: This text was generated based on current data from the Federal Institute for Drugs and Medical Devices (BfArM). Data updates are available daily (last on January 23, 2024, 12:00 p.m.). If you have any comments or questions, please contact [email protected].+++ +++
roj/news.de
Receive notifications